Frankfurt and the surrounding Rhine-Main region are one of the most active centers for the pharmaceuticals and biotechnology industries in Germany. The area’s industrial background and strategic investments in research and development have positioned Frankfurt as an influential hub in pharmaceutical innovation, especially in the fields of medical biotechnology. The FrankfurtRhineMain region is home to a high concentration of industrial parks, making it the largest business sector in the metropolitan area. Key to its success is the House of Pharma, a central hub that facilitates collaboration between large companies, academic institutions, and startups. Additionally, the Frankfurter Innovationszentrum Biotechnologie provides laboratory and office space for smaller life sciences companies, encouraging innovation and growth in the pharmaceuticals industry in Frankfurt. One of the region’s most significant assets is the Höchst Industrial Park, a historic, cutting-edge pharmaceutical and chemical business hub. Established in 1868 as a producer of tar dyes, the site has since grown into a global leader in pharmaceutical production. The park is home to over 90 companies and 22,000 employees, with pharmaceutical giant Sanofi serving as the largest player. Sanofi’s presence in Frankfurt is particularly notable, as the company produces up to one million insulin pens per day, supplying diabetes patients in over 80 countries. The industrial park also plays a vital role in the development and production of vaccines and other essential medicines. Sanofi’s Frankfurt site is its largest in Germany, employing over 6,000 people and 400 vocational trainees. The facility plays a critical role in the company’s global research and production operations. The site is also an important part of the European research network, focusing on key therapeutic areas such as immunology, oncology, cardiovascular diseases, and rare diseases. Sanofi’s research in Frankfurt-Höchst is at the forefront of developing advanced pharmaceuticals, including monoclonal antibodies and other innovative treatments.